Citi analyst Geoff Meacham lowered the firm’s price target on Biogen (BIIB) to $160 from $190 and keeps a Neutral rating on the shares. Ahead of the Q4 earnings, the firm updated models for its biotechnology and pharmaceuticals coverage. Higher-growth names like Eli Lilly (LLY) and Vertex VRTX) remain Citi’s favorites in the group, given their “strong demand” in key franchises and a lower impact from potential policy changes. The sector “looks tricky” in 2025 given negative sentiment, but growth expectations appear beatable with a focus on commercial execution, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Sage Rejects Biogen Bid but Could be Open to Other Offers
- M&A News: Sage Rejects Biogen’s $469M Takeover Bid over Valuation Concerns
- China’s DeepSeek sinks tech, AT&T reports Q4 beat: Morning Buzz
- Sage Therapeutics initiates strategic review, rejects Biogen proposal
- Biogen (NASDAQ:BIIB) and Eisai Win FDA’s OK on Alzheimer’s Drug Dosing